Scienion has announced that the company will produce protein microarray batches for clinical validation studies of proprietary biomarker panels of Protagen.
The batch sizes will comprise more than 1,000 arrays.
Additionally, the companies plan to jointly evaluate new platforms for multiplex analytics and to co-develop novel approaches up to proof-of-concept levels under a strategic partnership.
Dr Peter Schulz-Knappe of Protagen said: 'For the multicentre, international clinical validation studies of our multiplex diagnostic markers for the early detection of multiple sclerosis and the differential diagnosis of prostate cancer it is essential to ensure a consistently high statistical reliability for diagnostic conclusions.
'Scienion's sciflexarrayer technology allows the manufacturing of protein microarray batches each with more than 3,500 single proteins in highest quality and reproducibility.
'Thereby, we can realise the needed consistency in quality and properties throughout three stages: from spot to spot, from array to array and from batch to batch,' he added.
